Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy
Yi Lai, Gail D Thomas, Yongping Yue, Hsiao T Yang, Dejia Li, Chun Long, Luke Judge, Brian Bostick, Jeffrey S Chamberlain, Ronald L Terjung, Dongsheng Duan, Yi Lai, Gail D Thomas, Yongping Yue, Hsiao T Yang, Dejia Li, Chun Long, Luke Judge, Brian Bostick, Jeffrey S Chamberlain, Ronald L Terjung, Dongsheng Duan
Abstract
Sarcolemma-associated neuronal NOS (nNOS) plays a critical role in normal muscle physiology. In Duchenne muscular dystrophy (DMD), the loss of sarcolemmal nNOS leads to functional ischemia and muscle damage; however, the mechanism of nNOS subcellular localization remains incompletely understood. According to the prevailing model, nNOS is recruited to the sarcolemma by syntrophin, and in DMD this localization is altered. Intriguingly, the presence of syntrophin on the membrane does not always restore sarcolemmal nNOS. Thus, we wished to determine whether dystrophin functions in subcellular localization of nNOS and which regions may be necessary. Using in vivo transfection of dystrophin deletion constructs, we show that sarcolemmal targeting of nNOS was dependent on the spectrin-like repeats 16 and 17 (R16/17) within the rod domain. Treatment of mdx mice (a DMD model) with R16/17-containing synthetic dystrophin genes effectively ameliorated histological muscle pathology and improved muscle strength as well as exercise performance. Furthermore, sarcolemma-targeted nNOS attenuated alpha-adrenergic vasoconstriction in contracting muscle and improved muscle perfusion during exercise as measured by Doppler and microsphere circulation. In summary, we have identified the dystrophin spectrin-like repeats 16 and 17 as a novel scaffold for nNOS sarcolemmal targeting. These data suggest that muscular dystrophy gene therapies based on R16/17-containing dystrophins may yield better clinical outcomes than the current therapies.
Figures
References
- Stamler J.S., Meissner G. Physiology of nitric oxide in skeletal muscle. Physiol. Rev. 2001;81:209–237.
- Thomas G.D., et al. Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc. Natl. Acad. Sci. U. S. A. 1998;95:15090–15095. doi: 10.1073/pnas.95.25.15090.
- Sander M., et al. Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. U. S. A. 2000;97:13818–13823. doi: 10.1073/pnas.250379497.
- Kunkel L.M. 2004 William Allan Award address. Cloning of the DMD gene. Am. J. Hum. Genet. 2005;76:205–214. doi: 10.1086/428143.
- Mendell J.R., Engel W.K., Derrer E.C. Duchenne muscular dystrophy: functional ischemia reproduces its characteristic lesions. Science. 1971;172:1143–1145. doi: 10.1126/science.172.3988.1143.
- Parker J.M., Mendell J.R. Proximal myopathy induced by 5-HT-imipramine simulates Duchenne dystrophy. Nature. 1974;247:103–104.
- Brenman J.E., Chao D.S., Xia H., Aldape K., Bredt D.S. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell. 1995;82:743–752. doi: 10.1016/0092-8674(95)90471-9.
- Chang W.J., et al. Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. Proc. Natl. Acad. Sci. U. S. A. 1996;93:9142–9147. doi: 10.1073/pnas.93.17.9142.
- Percival J.M., et al. Functional deficits in nNOSmu-deficient skeletal muscle: myopathy in nNOS knockout mice. PLoS ONE. 2008;3:e3387.
- Kobayashi Y.M., et al. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature. 2008;456:511–515. doi: 10.1038/nature07414.
- Ahn A.H., Kunkel L.M. Syntrophin binds to an alternatively spliced exon of dystrophin. J. Cell Biol. 1995;128:363–371. doi: 10.1083/jcb.128.3.363.
- Suzuki A., Yoshida M., Ozawa E. Mammalian alpha 1- and beta 1-syntrophin bind to the alternative splice- prone region of the dystrophin COOH terminus. J. Cell Biol. 1995;128:373–381. doi: 10.1083/jcb.128.3.373.
- Yang B., Jung D., Rafael J.A., Chamberlain J.S., Campbell K.P. Identification of alpha-syntrophin binding to syntrophin triplet, dystrophin, and utrophin. J. Biol. Chem. 1995;270:4975–4978. doi: 10.1074/jbc.270.10.4975.
- Yoshida M., et al. Biochemical evidence for association of dystrobrevin with the sarcoglycan-sarcospan complex as a basis for understanding sarcoglycanopathy. Hum. Mol. Genet. 2000;9:1033–1040. doi: 10.1093/hmg/9.7.1033.
- Crawford G.E., et al. Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J. Cell Biol. 2000;150:1399–1410. doi: 10.1083/jcb.150.6.1399.
- Yue Y., Liu M., Duan D. C-terminal truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double knock-out mice. Mol. Ther. 2006;14:79–87. doi: 10.1016/j.ymthe.2006.01.007.
- Hillier B.J., et al. Unexpected modes of PDZ domain scaffolding revealed by structure of nNOS-syntrophin complex. Science. 1999;284:812–815. doi: 10.1126/science.284.5415.812.
- Tochio H., Zhang Q., Mandal P., Li M., Zhang M. Solution structure of the extended neuronal nitric oxide synthase PDZ domain complexed with an associated peptide. Nat. Struct. Biol. 1999;6:417–421. doi: 10.1038/8216.
- Kameya S., et al. alpha1-syntrophin gene disruption results in the absence of neuronal- type nitric-oxide synthase at the sarcolemma but does not induce muscle degeneration. J. Biol. Chem. 1999;274:2193–2200. doi: 10.1074/jbc.274.4.2193.
- Adams M.E., Mueller H.A., Froehner S.C. In vivo requirement of the alpha-syntrophin PDZ domain for the sarcolemmal localization of nNOS and aquaporin-4. J. Cell Biol. 2001;155:113–122. doi: 10.1083/jcb.200106158.
- Chao D.S., et al. Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy. J. Exp. Med. 1996;184:609–618. doi: 10.1084/jem.184.2.609.
- Wells K.E., et al. Relocalization of neuronal nitric oxide synthase (nNOS) as a marker for complete restoration of the dystrophin associated protein complex in skeletal muscle. Neuromuscul. Disord. 2003;13:21–31. doi: 10.1016/S0960-8966(02)00191-8.
- Judge L.M., Haraguchi M., Chamberlain J.S. Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex. J. Cell Sci. 2006;119:1537–1546. doi: 10.1242/jcs.02857.
- Grady R.M., et al. Role for alpha-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat. Cell Biol. 1999;1:215–220. doi: 10.1038/12034.
- Lai Y., et al. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat. Biotechnol. 2005;23:1435–1439. doi: 10.1038/nbt1153.
- Harper S.Q., et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 2002;8:253–261. doi: 10.1038/nm0302-253.
- Gregorevic P., et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med. 2004;10:828–834. doi: 10.1038/nm1085.
- Ghosh A., Yue Y., Long C., Bostick B., Duan D. Efficient whole-body transduction with trans-splicing adeno-associated viral vectors. Mol. Ther. 2007;15:750–755.
- Megeney L.A., Kablar B., Garrett K., Anderson J.E., Rudnicki M.A. MyoD is required for myogenic stem cell function in adult skeletal muscle. Genes Dev. 1996;10:1173–1183. doi: 10.1101/gad.10.10.1173.
- Dudley R.W., et al. Sarcolemmal damage in dystrophin deficiency is modulated by synergistic interactions between mechanical and oxidative/nitrosative stresses. Am. J. Pathol. 2006;168:1276–1287. doi: 10.2353/ajpath.2006.050683.
- Li S., et al. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy. Hum. Mol. Genet. 2006;15:1610–1622. doi: 10.1093/hmg/ddl082.
- Miyagoe-Suzuki Y., Takeda S.I. Association of neuronal nitric oxide synthase (nNOS) with alpha1-syntrophin at the sarcolemma. Microsc. Res. Tech. 2001;55:164–170. doi: 10.1002/jemt.1167.
- Albrecht D.E., Froehner S.C. Syntrophins and dystrobrevins: defining the dystrophin scaffold at synapses. Neurosignals. 2002;11:123–129. doi: 10.1159/000065053.
- Kone B.C., Kuncewicz T., Zhang W., Yu Z.Y. Protein interactions with nitric oxide synthases: controlling the right time, the right place, and the right amount of nitric oxide. Am. J. Physiol. Renal Physiol. 2003;285:F178–F190.
- Torelli S., et al. Absence of neuronal nitric oxide synthase (nNOS) as a pathological marker for the diagnosis of Becker muscular dystrophy with rod domain deletions. Neuropathol. Appl. Neurobiol. 2004;30:540–545. doi: 10.1111/j.1365-2990.2004.00561.x.
- Kone B.C. Protein-protein interactions controlling nitric oxide synthases. Acta Physiol. Scand. 2000;168:27–31. doi: 10.1046/j.1365-201x.2000.00629.x.
- Harris B.Z., Lim W.A. Mechanism and role of PDZ domains in signaling complex assembly. J. Cell. Sci. 2001;114:3219–3231.
- Abdelmoity A., Padre R.C., Burzynski K.E., Stull J.T., Lau K.S. Neuronal nitric oxide synthase localizes through multiple structural motifs to the sarcolemma in mouse myotubes. FEBS Lett. 2000;482:65–70. doi: 10.1016/S0014-5793(00)02038-X.
- Xia H., Winokur S.T., Kuo W.L., Altherr M.R., Bredt D.S. Actinin-associated LIM protein: identification of a domain interaction between PDZ and spectrin-like repeat motifs. J. Cell Biol. 1997;139:507–515. doi: 10.1083/jcb.139.2.507.
- Roberts R.G., Coffey A.J., Bobrow M., Bentley D.R. Exon structure of the human dystrophin gene. Genomics. 1993;16:536–538. doi: 10.1006/geno.1993.1225.
- Djinovic-Carugo K., Young P., Gautel M., Saraste M. Structure of the alpha-actinin rod: molecular basis for cross-linking of actin filaments. Cell. 1999;98:537–546. doi: 10.1016/S0092-8674(00)81981-9.
- Calvert R., Kahana E., Gratzer W.B. Stability of the dystrophin rod domain fold: evidence for nested repeating units. Biophys. J. 1996;71:1605–1610. doi: 10.1016/S0006-3495(96)79363-3.
- Menhart N. Hybrid spectrin type repeats produced by exon-skipping in dystrophin. Biochim. Biophys. Acta. 2006;1764:993–999.
- Yue Y., et al. A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol. Ther. 2008;16:1944–1952. doi: 10.1038/mt.2008.207.
- Sampaolesi M., et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature. 2006;444:574–579. doi: 10.1038/nature05282.
- England S.B., et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature. 1990;343:180–182. doi: 10.1038/343180a0.
- Ausubel, F.M., et al., editors. 1995.Current protocols in molecular biology. John Wiley and Sons. New York, New York, USA.
- Thanh L.T., Nguyen T.M., Helliwell T.R., Morris G.E. Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin. Am. J. Hum. Genet. 1995;56:725–731.
- Hope B.T., Michael G.J., Knigge K.M., Vincent S.R. Neuronal NADPH diaphorase is a nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 1991;88:2811–2814. doi: 10.1073/pnas.88.7.2811.
- Bulfield G., Siller W.G., Wight P.A., Moore K.J. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl. Acad. Sci. U. S. A. 1984;81:1189–1192. doi: 10.1073/pnas.81.4.1189.
- Chapman V.M., Miller D.R., Armstrong D., Caskey C.T. Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. Proc. Natl. Acad. Sci. U. S. A. 1989;86:1292–1296. doi: 10.1073/pnas.86.4.1292.
- Li D., Yue Y., Duan D. Preservation of muscle force in mdx3cv mice correlates with low-level expression of a near full-length dystrophin protein. Am. J. Pathol. 2008;172:1332–1341. doi: 10.2353/ajpath.2008.071042.
- Ervasti J.M., Campbell K.P. Membrane organization of the dystrophin-glycoprotein complex. Cell. 1991;66:1121–1131. doi: 10.1016/0092-8674(91)90035-W.
- Yang H.T., Dinn R.F., Terjung R.L. Training increases muscle blood flow in rats with peripheral arterial insufficiency. J. Appl. Physiol. 1990;69:1353–1359.
- Flaim S.F., Zelis R.F. Regional distribution of cardiac output in conscious rats at rest and during exercise. Effects of diltiazem. Chest. 1980;78:187–192.
- Janssen B., Debets J., Leenders P., Smits J. Chronic measurement of cardiac output in conscious mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002;282:R928–R935.
Source: PubMed